Thyroid dysfunctions induced by tyrosine kinase inhibitors

Expert Opinion on Drug Safety

Volumn 13, Issue 6, 2014, Pages 723-733

  Fallahi, Poupak ^a   Ferrari, Silvia M ^a   Vita, Roberto ^b   Di Domenicantonio, Andrea ^a   Corrado, Alda ^a   Benvenga, Salvatore ^b   Antonelli, Alessandro ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Axitinib; Dasatinib; Hyperthyroidism; Hypothyroidism; Imatinib; Motesanib; Nilotinib; Pazopanib; Sorafenib; Sunitinib; Thyroid cancer; Thyroid dysfunctions; Tivozanib; Tyrosine kinase inhibitors; Vandetanib

Indexed keywords

AXITINIB; DASATINIB; IMATINIB; LIOTHYRONINE; MOTESANIB; NILOTINIB; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; THYROTROPIN; TIVOZANIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; THYROID HORMONE;

CHRONIC MYELOID LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; DEIODINATION; DERMATOFIBROSARCOMA PROTUBERANS; GASTROINTESTINAL TUMOR; HORMONE SUBSTITUTION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INCIDENCE; KIDNEY CARCINOMA; META ANALYSIS (TOPIC); NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RISK FACTOR; SUBTOTAL THYROIDECTOMY; THYROID DISEASE; THYROID FUNCTION; THYROID FUNCTION TEST; THYROID WEIGHT; CHEMICALLY INDUCED; DRUG MONITORING; PATHOPHYSIOLOGY; PROCEDURES;

ANTINEOPLASTIC AGENTS; DRUG MONITORING; HUMANS; PROTEIN KINASE INHIBITORS; THYROID DISEASES; THYROID FUNCTION TESTS; THYROID HORMONES;

EID: 84901359556     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.913021     Document Type: Review

References (88)

1. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172-87 (Pubitemid 41058349
2. Tolmachev V, Stone-Elander S, Orlova A. Radiolabelled receptor-Tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: Prospects and pitfalls. Lancet Oncol 2010;11:992-1000
3. Sarlis NJ, Benvenga S. Molecular signaling in thyroid cancer. Cancer Treat Res 2004;122:237-64
4. Di Marco V, De Vita F, Koskinas J, et al. Sorafenib: From literature to clinical practice. Ann Oncol 2013;24:ii30-7
5. Chau NG, Haddad RI. Vandetanib for the treatment of medullary thyroid cancer. Clin Cancer Res 2013;19:524-9
6. Villanueva A, Hernandez-Gea V, Llovet JM. Medical therapies for hepatocellular carcinoma: A critical view of the evidence. Nat Rev Gastroenterol Hepatol 2013;10:34-42
7. Stommel JM, Kimmelman AC, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007;318:287-90 (Pubitemid 47574858
8. Sherman SI. Lessons learned and questions unanswered from use of multitargeted kinase inhibitors in medullary thyroid cancer. Oral Oncol 2013;49:707-10
9. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24 (Pubitemid 46089672
10. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34 (Pubitemid 46089673
11. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006;368:1329-38 (Pubitemid 44528723
12. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-300 (Pubitemid 46630787
13. Haddad RI. New developments in thyroid cancer. J Natl Compr Canc Netw 2013;11:705-7
14. Antonelli A, Fallahi P, Ferrari SM, et al. Dedifferentiated thyroid cancer: A therapeutic challenge. Biomed Pharmacother 2008;62:559-63
15. Fallahi P, Ferrari SM, Santini F, et al. Sorafenib and thyroid cancer. BioDrugs 2013;27:615-28
16. Antonelli A, Bocci G, La Motta C, et al. Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. J Clin Endocrinol Metab 2011;96:E288-96
17. Antonelli A, Bocci G, Fallahi P, et al. CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. J Clin Endocrinol Metab 2014;99(4):E572-81
18. Benvenga S, Ruggeri RMN, Trimarchi F. Thyroid and drugs. In: Monaco F, editor. Thyroid diseases. CRC, Hoboken; 2012. p: 469-92
19. Sodergren SC, White A, Efficace F, et al. Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumours on behalf of the EORTC Quality of Life Group. Crit Rev Oncol Hematol 2014. [Epub ahead of print
20. Torino F, Corsello SM, Longo R, et al. Hypothyroidism related to tyrosine kinase inhibitors: An emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 2009;6:219-28
21. Makita N, Iiri T. Tyrosine kinase inhibitor-induced thyroid disorders: A review and hypothesis. Thyroid 2013;23:151-9
22. Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007;99:81-3
23. Wong E, Rosen LS, Mulay M, et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 2007;17:351-5 (Pubitemid 46776140
24. Mannavola D, Coco P, Vannucchi G, et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 2007;92:3531-4 (Pubitemid 47435331
25. Wolter P, Stefan C, Decallonne B, et al. The clinical implications of sunitinibinduced hypothyroidism: A prospective evaluation. Br J Cancer 2008;99:448-54
26. Shinohara N, Takahashi M, Kamishima T, et al. The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma. Br J Cancer 2011;104:241-7
27. Funakoshi T, Shimada YJ. Risk of hypothyroidism in patients with cancer treated with sunitinib: A systematic review and meta-Analysis. Acta Oncol 2013;52:691-702
28. Tamaskar I, Bukowski R, Elson P, et al. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol 2008;19:265-8 (Pubitemid 351201706
29. Clement P, Stefan C, Decallonne P, et al. Thyroid dysfunction in patients (pts) with metastatic renal cell cancer (RCC) treated with sorafenib [abstract 16145]. American Society of Clinical Oncology 44th Annual Meeting (ASCO); 30 May-3 June 2008; Chicago, USA
30. Schmidinger M, Vogl UM, Bojic M, et al. Hypothyroidism in patients with renal cell carcinoma: Blessing or curse?. Cancer 2011;117:534-44
31. Riesenbeck LM, Bierer S, Hoffmeister I, et al. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. World J Urol 2011;29:807-13
32. Desai J, Yassa L, Marqusee E, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006;145:660-4 (Pubitemid 46768841
33. Grossmann M, Premaratne E, Desai J, Davis ID. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf) 2008;69:669-72
34. Salem AK, Fenton MS, Marion KM, Hershman JM. Effect of sunitinib on growth and function of FRTL-5 thyroid cells. Thyroid 2008;18:631-5 (Pubitemid 351918450
35. Kamba T, Tam BY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006;290:H560-76
36. Makita N, Miyakawa M, Fujita T, Iiri T. Sunitinib induces hypothyroidism with a markedly reduced vascularity. Thyroid 2010;20:323-6
37. Braun D, Kim TD, le Coutre P, et al. Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport. J Clin Endocrinol Metab 2012;97:E100-5
38. Antonelli A, Fallahi P, Ferrari SM, et al. RET TKI: Potential role in thyroid cancers. Curr Oncol Rep 2012;14:97-104
39. Miyake H, Kurahashi T, Yamanaka K, et al. Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: A prospective evaluation. Urol Oncol 2010;28:515-19
40. Illouz F, Laboureau-Soares S, Dubois S, et al. Tyrosine kinase inhibitors and modifications of thyroid function tests: A review. Eur J Endocrinol 2009;160:331-6
41. Feldt S, Schüssel K, Quinzler R, et al. Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: A cohort study. Eur J Cancer 2012;48:974-81
42. Kitajima K, Takahashi S, Maeda T, et al. Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: Comparison with thyroid function. Eur J Radiol 2012;81:2060-5
43. Abdulrahman RM, Verloop H, Hoftijzer H, et al. Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. J Clin Endocrinol Metab 2010;95:3758-62
44. Antonelli A, Fallahi P, Ferrari SM, et al. New targeted therapies for thyroid cancer. Curr Genomics 2011;12:626-31
45. Dranitsaris G, Schmitz S, Broom RJ. Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: A systematic review and indirect comparison of safety and efficacy. J Cancer Res Clin Oncol 2013;139:1917-26
46. LaPlant KD, Louzon PD. Pazopanib: An oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma. Ann Pharmacother 2010;44:1054-60
47. Wolter P, McCann L, Sternberg CN, et al. Incidence of thyroid dysfunction in renal cell carcinoma (RCC) patients treated with pazopanib in prospective clinical trials [abstract 4633]. American Society of Clinical Oncology 47th Annual Meeting; 3-7 June 2011; Chicago, USA
48. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 2010;28:1061-8
49. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;369:722-31
50. Matrana MR, Duran C, Shetty A, et al. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. Eur J Cancer 2013;49:3169-75
51. de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, et al. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 2007;92:3466-9 (Pubitemid 47435321
52. de Groot JW, Zonnenberg BA, Plukker JT, et al. Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther 2005;78:433-8 (Pubitemid 41393678
53. Dora JM, Leie MA, Netto B, et al. Lack of imatinib-induced thyroid dysfunction in a cohort of non-Thyroidectomized patients. Eur J Endocrinol 2008;158:771-2 (Pubitemid 351639617
54. de Diego García P, Trincado Aznar P, Playán Usón J, Albero Gamboa R. Levothyroxine therapy and imatinib. Endocrinol Nutr 2008;55:304-7
55. Kim TD, Schwarz M, Nogai H, et al. Thyroid dysfunction caused by secondgeneration tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia. Thyroid 2010;20:1209-14
56. Yoshizato T, Nannya Y, Yoshiki Y, et al. Nilotinib-induced hypothyroidism in a patient with chronic myeloid leukemia. Int J Hematol 2011;93:400-2
57. Karras S, Anagnostis P, Krassas GE. Vandetanib for the treatment of thyroid cancer: An update. Expert Opin Drug Metab Toxicol 2014;10:469-81
58. Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial. J Clin Oncol 2012;30:134-41
59. Giunti S, Antonelli A, Amorosi A, Santarpia L. Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma. Int J Endocrinol 2013;2013:803171
60. Robinson BG, Paz-Ares L, Krebs A, et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010;95:2664-71
61. Gross-Goupil M, François L, Quivy A, Ravaud A. Axitinib: A review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma. Clin Med Insights Oncol 2013;7:269-77
62. King JW, Lee SM. Axitinib for the treatment of advanced non-small-cell lung cancer. Expert Opin Investig Drugs 2013;22:765-73
63. Fujiwara Y, Kiyota N, Chayahara N, et al. Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: Results from phase I studies in Japanese patients. Invest New Drugs 2012;30:1055-64
64. Ueda T, Uemura H, Tomita Y, et al. Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: Subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial. Jpn J Clin Oncol 2013;43:616-28
65. Hutson TE, Lesovoy V, Al-Shukri S, et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: A randomised open-label phase 3 trial. Lancet Oncol 2013;14:1287-94
66. Karam JA, Devine CE, Urbauer DL, et al. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. Eur Urol 2014. [Epub ahead of print
67. Raghav KP, Blumenschein GR. Motesanib and advanced NSCLC: Experiences and expectations. Expert Opin Investig Drugs 2011;20:859-69
68. De Boer RH, Kotasek D, White S, et al. Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer. Breast Cancer Res Treat 2012;135:241-52
69. Antonelli A, Fallahi P, Ulisse S, et al. New targeted therapies for anaplastic thyroid cancer. Anticancer Agents Med Chem 2012;12:87-93
70. Sherman SI, Wirth LJ, Droz JP, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008;359:31-42 (Pubitemid 351931094
71. Schlumberger MJ, Elisei R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009;27:3794-801
72. Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: Results from a phase III trial. J Clin Oncol 2013;31:3791-9
73. Niwakawa M, Yamaguchi R, Onozawa Y, et al. Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors. Cancer Sci 2013;104:1039-44
74. Faris JE, Moore AF, Daniels GH. Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: A case report. Thyroid 2007;17:1147-9 (Pubitemid 350207759
75. Fuertes Zamorano N, De Miguel Novoa MP, Molino González A, et al. Thyroid dysfunction in patients with advanced renal cell carcinoma treated with sunitinib: A multifactorial issue. Endocrinol Nutr 2010;57:486-91
76. Sato S, Muraishi K, Tani J, et al. Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma. Endocr J 2010;57:873-80
77. Sakurai K, Fukazawa H, Arihara Z, Yoshida K. Sunitinib-induced thyrotoxicosis followed by persistent hypothyroidism with shrinkage of thyroid volume. Tohoku J Exp Med 2010;222:39-44
78. Daimon M, Kato T, Kaino W, et al. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma. Jpn J Clin Oncol 2012;42:742-7
79. van Doorn L, Eskens FA, Visser TJ, et al. Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma. Thyroid 2011;21:197-202
80. Konca Degertekin C, Coşkun U, Baloş Torüner F, et al. Hyperthyroidism and thyroid autoimmunity induced by sorafenib in metastatic renal cell cancer. Endocrine 2012;42:756-7
81. Haraldsdottir S, Li Q, Villalona-Calero MA, et al. Case of sorafenib-induced thyroid storm. J Clin Oncol 2013;31:e262-4
82. Ohba K, Takayama T, Matsunaga H, et al. Inappropriate elevation of serum thyrotropin levels in patients treated with axitinib. Thyroid 2013;23:443-8
83. Wolter P, Stefan C, Decallonne B, et al. Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC) [abstract 5126]. American Society of Clinical Oncology 44th Annual Meeting (ASCO); 30 May-3 June2008; Chicago, USA
84. Shinohara N, Takahashi M, Kamishima T, et al. Efficacy and thyroidal effects of sunitinib in Japanese patients with metastatic renal cell carcinoma: Hypothyroidism and thyroid atrophy as potential biomarkers for sunitinib?. [abstract e16097]. American Society of Clinical Oncology 45th Annual Meeting (ASCO); 29 May-2 June 2009; Orlando, USA
85. Sella A, Hercbergs AH, Hanovich E, Kovel S. Does sunitinib-induced hypothyroidism play a role in the activity of sunitinib in metastatic renal cell carcinomä. Chemotherapy 2012;58:200-5
86. Brown RL. Tyrosine kinase inhibitorinduced hypothyroidism: Incidence, etiology, and management. Target Oncol 2011;6:217-26
87. Garfield D, Hercbergs A, Davis P. Unanswered questions regarding the management of sunitinib-induced hypothyroidism. Nat Clin Pract Oncol 2007;4:674
88. Bladou F, Gravis G, Sabatier R, et al. Hypothyroidism and survival during sunitinib therapy in metastatic renal cell carcinoma (mRCC): A prospective observational analysis [abstract e15013]. American Society of Clinical Oncology 46th American Society of Clinical Oncology Annual Meeting (ASCO); 4-8 June 2010; Chicago, USA